Celgene reports updated ORR of 82% for anti-BCMA CAR T therapy in MM

The Juno Therapeutics Inc. subsidiary of Celgene Corp. (NASDAQ:CELG) reported updated data from the Phase I/II EVOLVE trial to treat relapsed and/or refractory multiple myeloma in patients who have received at least three prior regimens showing that JCARH125 led to an overall response rate (ORR) of 82% among 44 heavily pretreated patients at a median follow-up of 11 weeks. Grade 3/4 cytokine release syndrome (CRS) was reported in 9% of patients and grade 3/4 neurological events were reported in 7% of patients. Data were presented at the American Society of Hematology (ASH) meeting in San Diego...